viewInvitrocue Ltd

InvitroCue Ltd to enter oncology testing market with 3D cell­based platform


InvitroCue Ltd (ASX:IVQ), a biotechnology company specialising in cell-based and image-based analytics, will enter the oncology testing market for drugs to provide data points in selected solid tumours.

The company will use 3D cell-based technology to culture patient derived cancer cells in its laboratories for testing against a panel of approved drugs and new drug candidates.

This will enable biopharmaceutical companies and medical researchers to understand the impact of cancer treatments prior to conducting time consuming and expensive clinical trials.

Subsequently, InvitroCue’s technology may create a new market for personalised drug testing using FDA approved drugs to improve individual treatment outcomes in selected solid tumours.

InvitroCue has also entered into a research collaboration with a Chinese medical university and is seeking clinical partnerships in Australia, Europe and USA.

In February, the company had signed up with the National Cancer Centre Singapore to develop applications to improve treatment outcomes in primary liver cancer patients.

InvitroCue is well funded with $2 million cash as on 31 March, 2016.


Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

Quick facts: Invitrocue Ltd

Price: - AUD

Market: ASX
Market Cap: -

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Invitrocue Ltd named herein, including the promotion by the Company of Invitrocue Ltd in any Content on the Site, the Company receives from...


2 min read